Rapamycin derivatives for treating neuroblastoma
AssigneeNovartis AG
InventorHans Schaller
Life of this patent
Estimating the term…
Abstract
A rapamycin derivative for use in the treatment of neuroblastome, optionally in combination with a second drug substance.
Claims10
A method for treating neuroblastomas, comprising administering to a subject in need thereof a therapeutically effective amount of a rapamycin derivative.
(canceled)
(canceled)
A pharmaceutical package comprising a rapamycin derivative and at least one second drug substance, and instructions for combined administration wherein combinations of a rapamycin derivative with an LFA-1 inhibitor, or MEK inhibitor and/or a tyrosine kinase inhibitor are excluded.
A pharmaceutical package comprising a rapamycin derivative and instructions for combined administration with at least one second drug substance, wherein combinations of a rapamycin derivative with an LFA-1 inhibitor, or MEK inhibitor and/or a tyrosine kinase inhibitor are excluded.
A pharmaceutical package comprising at least one second drug substance and instructions for combined administration with a rapamycin derivative, wherein combinations of a rapamycin derivative with an LFA-1 inhibitor, or MEK inhibitor and/or a tyrosine kinase inhibitor are excluded,
Dependencies are inferred from the claim text.